May 14, 2020
U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year
May 11, 2020
Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 05, 2020
Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion
Apr 23, 2020
Portola Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 11, 2020
Mar 16, 2020
Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds
Feb 24, 2020
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Feb 12, 2020
Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020
Feb 03, 2020
Portola Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President and Chief Medical Officer
Dec 23, 2019
Portola Pharmaceuticals to Webcast Corporate Update on January 14, 2020
Dec 17, 2019
Portola Pharmaceuticals to Support New American Heart Association Initiative to Address Hemorrhagic Stroke
Aug 22, 2019
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Aug 05, 2019
U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa
Jul 17, 2019
Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019